Today: 9 June 2026
Apple stock in focus as AI-spending nerves grow — what to watch when AAPL trading returns
16 February 2026
2 mins read

Apple stock in focus as AI-spending nerves grow — what to watch when AAPL trading returns

NEW YORK, Feb 16, 2026, 10:02 AM EST — The market has closed.

  • Apple slipped roughly 2.3% to finish at $255.78, with the drop coming just before the U.S. market holiday.
  • Investors are once again scrutinizing big tech, casting doubt on the payoff from massive AI investments and putting valuations under the microscope.
  • Coming up: Fed minutes land Feb. 18, with Apple’s annual shareholder meeting set for Feb. 24.

Apple Inc shares slipped roughly 2.3% to $255.78 on Friday. With U.S. markets closed Monday for Presidents Day, investors now face a pause before big tech can react when trading starts up again Tuesday.

So, Apple and the other megacaps hit the brakes, facing a new mood in the tape. Investors who once chased artificial intelligence at any cost now want to see when the spending finally delivers profit.

By early 2026, the tech heavyweights have lost staggering sums—billions, sometimes hundreds of billions—wiped from their market caps. Investors are starting to wonder if pouring so much money into AI will actually pay off at the levels those high valuations suggest, according to a Reuters analysis.

Apple shares now move less on iPhone headlines and more as a stand-in for the bigger “AI trade”—at least on a daily basis. Instead of boosting all tech stocks together, the market’s sorting out who it thinks will win and who won’t.

“You’ve clearly seen that breakdown in terms of the monolithic AI trade,” said Garrett Melson, portfolio strategist at Natixis Investment Managers Solutions, speaking to Reuters in a recent interview. Reuters

Apple is dealing with another round of regulatory attention. Last week, the U.S. Federal Trade Commission’s chairman pressed Apple CEO Tim Cook on claims Apple News favors left-leaning publishers while limiting exposure for conservative content, cautioning that actions outside consumer expectations “may violate the FTC Act.” Reuters reached out to Apple for comment, but the company hasn’t responded yet. Reuters

Traders are keeping an eye on the Federal Reserve’s meeting minutes set for Wednesday, combing through the details of the central bank’s policy debate as interest-rate bets keep driving big-tech stocks. Also landing that day: fresh numbers on housing starts and durable goods orders, per the U.S. Census Bureau’s schedule.

For Apple, the next big event lands on Feb. 24: that’s when the annual shareholder meeting kicks off at 8:00 a.m. Pacific.

After pulling back from recent highs, the stock may face a new test: some investors aren’t simply diving back into those crowded megacap tech bets. Instead, they’ll be watching for any hint that risk appetite in the sector has found its footing when markets open again.

The flip side is hard to miss: when investors view AI mostly as an expense with no clear return, and regulatory issues pile higher, Apple risks sliding along with peers—even during a routine, uneventful week for the company.

Big catalysts are coming up fast. U.S. markets get back to business Tuesday. Not long after, all eyes will turn to the Fed minutes on Feb. 18, with Apple’s annual meeting set for Feb. 24.

Stock Market Today

  • Glaukos (GKOS) Shares Show Volatility Amid 19% Undervaluation Claim
    June 9, 2026, 9:42 AM EDT. Glaukos (GKOS) shares rose 18% in the past week but fell nearly 9% over the last month, reflecting short-term volatility. The stock trades at $121.96, below its fair value estimate of $151.08, suggesting a 19.3% undervaluation. The company's focus on ophthalmic therapies, including iDose TR for glaucoma, underpins a potential shift in treatment approaches driven by an aging population and increasing glaucoma cases. Investors consider this a long-term growth opportunity, though realization depends on product adoption and reimbursement policies. Glaukos posted a one-year total shareholder return of 28.87%, indicating sustained momentum despite recent fluctuations. The valuation hinges on expectations of revenue growth, profitability turnaround, and premium earnings multiples typical of high growth firms.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Charles Schwab stock slips despite $27.8 billion January inflows as investors brace for Fed minutes
Previous Story

Charles Schwab stock slips despite $27.8 billion January inflows as investors brace for Fed minutes

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Next Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Go toTop